NeuroScience Research Center LLC

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease7 trials
• Obstructive sleep apnoea2 trials
• Parkinson disease2 trials
• Epilepsy1 trial

Phase

• Phase 38 trials
• Phase 23 trials
• Phase 41 trial

Status

• Completed5 trials
• Active, not recruiting3 trials
• Enrolling by invitation1 trial
• Recruiting1 trial
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Apnimed2 trials
• Cassava Sciences, Inc.2 trials
• Novo Nordisk A/S2 trials
• AriBio Co., Ltd.1 trial
• Biogen1 trial
• and 4 more

Running trials

• Recruiting

  A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

  NCT06765668· Phase 4· Impax Laboratories, LLC· Source

  Contact: Ryan Drake

• Enrolling by invitation

  Continuation Protocol for Obstructive Sleep Apnea (OSA)

  NCT06566820· Phase 3· Apnimed· Source

• Active, not recruiting

  Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

  NCT05531526· Phase 3· AriBio Co., Ltd.· Source

• Active, not recruiting

  A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

  NCT05399888· Phase 2· Biogen· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Eisai Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obstructive sleep apnoea1 recruiting
• Parkinson disease1 recruiting

Closed trials

• Completed

  A Study of NE3107 in Early Parkinson's

  NCT06757010· Phase 2· BioVie Inc.· Source

• Completed

  Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

  NCT05811247· Phase 3· Apnimed· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Cassava Sciences, Inc.· Source

• Withdrawn

  ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

  NCT05481905· Phase 2· Engrail Therapeutics INC· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source